Other substances

Hyaluronic acid

A nonsulfated glycosaminoglycan.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

108

Clinical trials

General information

Hyaluronic acid forms a viscous solution in water. It is a component of the extracellular matrix. Hyaluronic acid is used for osteoarthritis treatment or in ophthalmic surgery (DrugBank).

Hyaluronic acid on PubChem
Hyaluronic acid on Wikipedia

Synonyms

Hyaluronan; HA

Marketed as

AMO VITRAX; AMVISIC PLUS; CYSTISTAR; EUFLEXXA; HYALURONIC ACID; HYGEL; HYLASE; HYLINATE; RECOSYN; SYNVISC; VISCURE; YARDEL

CC(=O)NC1[C@@H]([C@@H](C(O[C@H]1COC[C@H]2[C@H](C([C@@H](OC2C(=O)O)OC[C@@H]3[C@@H](C(O[C@H](C3NC(=O)C)O)CO)O)(C)O)O)CO)O)CO[C@H]4C([C@@H]([C@@H](C(O4)C(=O)O)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Glycosaminoglycans induce conformational change in the SARS-CoV-2 Spike S1 Receptor Binding Domain. Spike protein Preprint	in vitro			Apr/29/2020
Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study 3CLpro Polysaccharide Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Nov/12/2020

AI-suggested references

Link	Publication date
A self-assembling nanoparticle vaccine targeting the conserved epitope of influenza virus hemagglutinin stem elicits a cross-protective immune response.	Nov/22/2022
Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway.	May/23/2020
An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.	Oct/14/2020
Safety of intramuscular COVID-19 vaccination in patients with haemophilia.	Jan/08/2022
Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results.	Feb/11/2021
Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.	May/03/2021
High-Sulfated Glycosaminoglycans Prevent Coronavirus Replication	Jun/15/2020
Identification of the SHREK Family of Proteins as Broad-Spectrum Host Antiviral Factors.	May/04/2021
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection	Aug/17/2021
Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins.	Apr/13/2021
OM-85 Broncho-Vaxom , a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells.	Oct/26/2021
The Efficacy of Early Additional Hemoperfusion Therapy for Severe COVID-19 Patients: A Prospective Cohort Study	Jun/18/2020
Nanobubble Ozone Stored in Hyaluronic Acid Decorated Liposomes: Antibacterial, Anti-SARS-CoV-2 Effect and Biocompatibility Tests	Jan/25/2022
A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice	Dec/15/2021
Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression	Sep/15/2021
Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity	Feb/03/2022
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	Dec/16/2021
Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs.	Jan/28/2021
The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain	Apr/06/2022
Inhalable nanocatchers for SARS-CoV-2 inhibition	Oct/02/2020
Crystal structure of inhibitor-bound human MSPL that can activate high pathogenic avian influenza	Apr/05/2021
A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model	Jan/03/2022
Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants	Jul/04/2020
Oral hymecromone decreases hyaluronan in human study participants	Jan/19/2021
Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.	Apr/27/2021
Cetylpyridinium chloride (CPC) reduces zebrafish mortality from influenza infection: Super-resolution microscopy reveals CPC interference with multiple protein interactions with phosphatidylinositol 4,5-bisphosphate in immune function	Aug/01/2020
SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network	Sep/30/2021
Viral Prefusion Targeting Using Entry Inhibitor Peptides: The Case of SARS-CoV-2 and Influenza A virus.	Jan/03/2022
Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of "Different Diseases with the Same Treatment" Based on Network Pharmacology	May/25/2021
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination	Jan/07/2022
A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro	May/29/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04437121	Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece	Completed		Apr/30/2020	May/24/2020
Alternative id - COV-EAT Interventions - Other: Online Survey about Dietary and Lifestyle Habits Study type - Observational Study results - No Results Available Locations - Department of Nutrition-Dietetics, Tríkala, Thessaly, Greece Study designs - Observational Model: Case-Crossover\|Time Perspective: Cross-Sectional Enrollment - 397 Age - 24 Months to 18 Years (Child, Adult) Outcome measures - Change in weight (child)\|Behaviour (child)\|Behaviour (parents)\|Physical Activity Levels (child)\|Screen Time (child)\|Sleep Duration (child)
NCT04339842	Eating Habits of Adults During the Quarantine	Completed		Apr/10/2020	May/31/2020
Alternative id - Nutr2020 Interventions - Other: Assessment of Dietary Changes in Adults in the Quarantine Study type - Observational Study results - No Results Available Locations - Online, Nicosia, Cyprus Study designs - Observational Model: Case-Only\|Time Perspective: Cross-Sectional Enrollment - 673 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Changes in the Eating Habits of Adults during the Quarantine
NCT04746092	The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19	Active, not recruiting		Jan/06/2021	May/24/2022
Alternative id - 1068-20 Interventions - Study type - Observational Study results - No Results Available Locations - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 630 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Capability of Haemato-oncology patients to generate antibodies against COVID-19 after infection and vaccination.\|Assess COVID19 morbidity rates\|Documentation of the vaccine side effects\|Comparison of antibody formation to COVID19 between haemato-oncology patients and healthy participants
NCT04710303	COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults	Recruiting	Phase 1	Mar/02/2021	Apr/01/2022
Alternative id - AW_001_ProVIVA-SA-1 Interventions - Biological: hAd5-S-Fusion+N-ETSD vaccine Study type - Interventional Study results - No Results Available Locations - Khayelitsha Clinical Research Site, Khayelitsha, South Africa Study designs - Allocation: Non-Randomized\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 35 Age - 18 Years to 50 Years (Adult) Outcome measures - Incidence of MAAEs and SAEs\|Incidence and severity of solicited local reactogenicity AEs\|Incidence and severity of solicited systemic reactogenicity AEs\|Incidence and severity of unsolicited AEs\|Incidence of changes of laboratory safety examinations\|Vital Sign - Temperature\|Vital Sign - Heart rate\|Vital Sign - Blood Pressure\|Vital Sign - Respiratory Rate\|GMFR in IgG titer\|GMT of S-specific, RBD-specific, and N-specific antibodies\|Percentage of participants who seroconverted\|GMFR in neutralizing antibody\|GMT of neutralizing antibody\|Seroconversion rate of neutralizing antibody\|New HIV infections in vaccine recipients
NCT04881396	Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine	Not yet recruiting		May/10/2021	Jun/01/2022
Alternative id - 69HCL21_0125\|2021-A00325-36 Interventions - Biological: Evaluation of the immunogenicity of the vaccine in haemodialysis patients Study type - Observational Study results - No Results Available Locations - Department of Nephrology, Hopital Edouard Herriot, Lyon, France\|Department of Nephrology, Centre Hospitalier Lyon Sud, Pierre Bénite, France Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 100 Age - 18 Years to 130 Years (Adult, Older Adult) Outcome measures - Seroconversion rate after vaccination with BTN162b2 mRNA cov-19 vaccine
NCT04828135	Dual MRI for Cardiopulmonary COVID-19 Long Haulers	Recruiting	Phase 2	May/26/2021	Dec/30/2022
Alternative id - Pro00107681 Interventions - Drug: Hyperpolarized 129Xenon gas Study type - Interventional Study results - No Results Available Locations - Duke Asthma, Allergy, and Airway Center, Durham, North Carolina, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Diagnostic Enrollment - 30 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in percentage of high barrier uptake on 129Xe MRI predicts outcomes as measured by FVC\|Change in percentage of low RBC transfer on 129Xe MRI predicts outcomes as measured by DLCO
NCT04649320	Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias	Recruiting		Nov/23/2020	Dec/31/2020
Alternative id - 1264/2020 Interventions - Other: questionnaire Study type - Observational Study results - No Results Available Locations - Medical University of Innsbruck, Innsbruck, Tyrol, Austria Study designs - Observational Model: Cohort\|Time Perspective: Other Enrollment - 300 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Influence of the COVID-19 pandemic on cancer patient's daily life
NCT04371510	Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients	Recruiting	Not Applicable	Apr/22/2020	Feb/22/2021
Alternative id - 20-PP-08 Interventions - Other: blood sample Study type - Interventional Study results - No Results Available Locations - CHU de nice, Nice, Alpes-Maritimes, France Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 115 Age - 18 Years to 85 Years (Adult, Older Adult) Outcome measures - Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation
NCT04403880	Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19	Active, not recruiting		May/13/2020	Mar/31/2022
Alternative id - HVTN 405/HPTN 1901\|5UM1AI068614-14 Interventions - Other: Sample collection Study type - Observational Study results - No Results Available Locations - Alabama Vaccine CRS, Birmingham, Alabama, United States\|UCLA CARE Center CRS, Los Angeles, California, United States\|Bridge HIV CRS, San Francisco, California, United States\|George Washington University CRS, Washington, District of Columbia, United States\|The Ponce de Leon Center CRS, Atlanta, Georgia, United States\|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States\|Adolescent & Young Adult Research at The CORE Center (AYAR at CORE), Chicago, Illinois, United States\|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States\|Johns Hopkins University CRS, Baltimore, Maryland, United States\|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States\|Fenway Health Clinical Research Site CRS, Boston, Massachusetts, United States\|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States\|Bronx Prevention Research Center CRS, Bronx, New York, United States\|Harlem Prevention Center CRS, New York, New York, United States\|Columbia P&S CRS, New York, New York, United States\|New York Blood Center CRS, New York, New York, United States\|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States\|Chapel Hill CRS, Chapel Hill, North Carolina, United States\|Penn Prevention CRS, Philadelphia, Pennsylvania, United States\|Vanderbilt Vaccine CRS, Nashville, Tennessee, United States\|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States\|Malawi CRS, Lilongwe, Malawi\|CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista, Callao, Peru\|San Miguel CRS, San Miguel, Lima, Peru\|Asociacion Civil Selva Amazonica (ACSA) CRS, Iquitos, Maynas, Peru\|Via Libra CRS, Lima, Peru\|Barranco CRS, Lima, Peru\|Josha Research CRS, Bloemfontein, South Africa\|Emavundleni CRS, Cape Town, South Africa\|Groote Schuur HIV CRS, Cape Town, South Africa\|Khayelitsha CRS / (CIDRI UCT), Cape Town, South Africa\|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa\|Chatsworth CRS, Chatsworth, South Africa\|Botha's Hill CRS, Durban, South Africa\|CAPRISA eThekwini CRS, Durban, South Africa\|Vulindlela CRS, Durban, South Africa\|Isipingo CRS, Isipingo, South Africa\|Kliptown Soweto CRS, Johannesburg, South Africa\|Soweto HVTN CRS, Johannesburg, South Africa\|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa\|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa\|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa\|Synexus Stanza Clinical Research Centre CRS, Pretoria, South Africa\|Rustenburg CRS, Rustenburg, South Africa\|Setshaba Research Centre CRS, Soshanguve, South Africa\|Tembisa Clinic 4 CRS, Tembisa, South Africa\|The Aurum Institute Tembisa Clinical Research Centre CRS, Tembisa, South Africa\|Tongaat CRS, Tongaat, South Africa\|Verulam CRS, Verulam, South Africa\|Matero Reference Clinic CRS, Lusaka, Zambia\|St Mary's CRS, Chitungwiza, Zimbabwe\|Zengeza CRS, Chitungwiza, Zimbabwe\|Seke South CRS, Harare, Zimbabwe Study designs - Observational Model: Cohort\|Time Perspective: Other Enrollment - 727 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Humoral responses to peptide antigens derived from SARS-CoV-2 structural proteins and regions of the spike protein not present in vaccines\|SARS-CoV-2-specific antibody binding response rate\|SARS-CoV-2-specific antibody binding response magnitude\|SARS-CoV-2-specific antibody binding response epitope specificity\|SARS-CoV-2-specific antibody neutralization response rate\|SARS-CoV-2-specific antibody neutralization response magnitude\|SARS-CoV-2-specific antibody neutralization response epitope specificity\|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response rate\|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response magnitude\|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response epitope specificity\|SARS-CoV-2-specific CD4+ and CD8+ T cell responses\|SARS-CoV-2-specific CD4+ and CD8+ T cell response rate\|SARS-CoV-2-specific CD4+ and CD8+ T cell response magnitude\|SARS-CoV-2-specific CD4+ and CD8+ T cell response functional profiling\|SARS-CoV-2-specific memory B cell characterization\|SARS-CoV-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants\|Detection of viral RNA in nasopharyngeal or nasal swab samples\|Response rate of SARS-CoV-2-specific binding antibodies in nasal samples\|Response magnitude of SARS-CoV-2-specific binding antibodies in nasal samples
NCT04512027	Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.	Completed	Not Applicable	Sep/15/2020	Oct/16/2020
Alternative id - CIMED - 002- 2020 Interventions - Other: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class\|Other: Standard of Care Study type - Interventional Study results - No Results Available Locations - Mazumdar Shaw Medical Centre, Bangalore, Karnataka, India Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 10 Age - 18 Years to 45 Years (Adult) Outcome measures - SarsCoV2 viral copy number\|b. Disease progression will be measured on a 7-point scale at 28 days. A 2-point change will be considered disease progression.
NCT04581928	Patients Reactions Towards Their Diagnosis as Having COVID-19	Recruiting		Oct/10/2020	Apr/15/2022
Alternative id - PR0020 Interventions - Study type - Observational Study results - No Results Available Locations - Asalam, Maadi, Cairo, Egypt Study designs - Observational Model: Cohort\|Time Perspective: Other Enrollment - 300 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to recovery
NCT05083013	Diabetes In Relation to Hospitalized COVID-19 Patents At Assiut University Hospital	Not yet recruiting		Nov/01/2021	Dec/31/2022
Alternative id - outcomes of DM in COVID-19 Interventions - Diagnostic Test: Reverse transcription polymerase chain reaction (RT-PCR)\|Diagnostic Test: Glycated haemoglobin (HbA1C)\|Radiation: High Resolution Computed Tomography (HRCT)\|Diagnostic Test: Routine Laboratory investigations\|Diagnostic Test: Random Blood Sugar (RBS) Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 160 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Mortality rates\|Hospital stays\|Need for ICU admission\|Need for ventilatory support\|Glycemic control\|Newly onset DM will appear among non-diabetic patients\|Acute complications of diabetes\|Exacerbation of chronic complications of diabetes\|Changes of diabetes management plan\|Incidence of other complications
NCT04407533	Dietary Intake and Eating Habits During the COVID-19 Pandemic	Active, not recruiting		May/25/2020	Aug/31/2022
Alternative id - 20-04-064 Interventions - Other: Diet tracking and survey Study type - Observational Study results - No Results Available Locations - McGill University - School of Human Nutrition, Montréal, Quebec, Canada Study designs - Observational Model: Ecologic or Community\|Time Perspective: Prospective Enrollment - 2020 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Dietary intake\|Diet quality\|Eating habits
NCT04534608	COVID-19 Child Health Investigation of Latent Disease in Hamburg	Active, not recruiting		May/11/2020	Mar/31/2021
Alternative id - PV7336 Interventions - Study type - Observational Study results - No Results Available Locations - Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany Study designs - Observational Model: Family-Based\|Time Perspective: Prospective Enrollment - 6000 Age - up to 18 Years (Child, Adult) Outcome measures - Acute infection by SARS-CoV-2\|Seroconversion for SARS-CoV-2\|Immune phenotyping\|HLA Typing\|Matabolomics
NCT04605952	Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive	Completed		Jul/01/2020	Aug/30/2020
Alternative id - 152473 Interventions - Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days Study type - Observational Study results - No Results Available Locations - Dr.Deb Sanjay Nag, Jamshedpur, Jharkhand, India Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 201 Age - 18 Years to 60 Years (Adult) Outcome measures - Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days
NCT04940871	Study to Assess the Efficacy and Safety of Favipiravir-HU	Not yet recruiting	Phase 2	Jun/01/2021	Dec/01/2022
Alternative id - HUN-FAVI-02 Interventions - Drug: Favipiravir HU 200 mg hard capsules\|Drug: Placebo HU Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 80 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - PRIM1_ the percentage of virus copy number\|SEC1_mortality rate\|SEC2_respiratory failure\|SEC3_ intensive care\|SEC4_non-invasive respiratory support\|SEC5_ invasive respiratory support\|SEC6_ Acute Respiratory Distress Syndrome
NCT04445493	EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )	Recruiting		Mar/01/2021	Dec/01/2022
Alternative id - EPISODE-PH-COVID Interventions - Device: MindRhythm Harmony Study type - Observational Study results - No Results Available Locations - Wayne State University, Detroit, Michigan, United States Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 250 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Prevalence of COVID-19 infection in suspected stroke population\|Quality head pulse recordings
NCT05091515	Thermoregulatory Reactions of Medical Workers Who Use Personal Protective Equipment From Biological Hazards	Completed		Mar/29/2021	May/31/2021
Alternative id - PPE-05 Interventions - Other: Personal protective equipment from biological hazard Study type - Observational Study results - No Results Available Locations - Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 25 Age - 18 Years to 55 Years (Adult) Outcome measures - Skin thermometry\|Hygrometry under costume\|Electrocardiography\|Blood pressure\|Heart rate\|Breathing rate\|Air thermometry and hygrometry\|Oxygenation
NCT04377750	The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation	Recruiting	Phase 4	Apr/08/2020	May/08/2021
Alternative id - 0224-20-HMO-CTIL Interventions - Drug: Tocilizumab Study type - Interventional Study results - No Results Available Locations - Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel\|Barzilai Medical Center, Ashkelon, Israel\|Wolfson Medical Center, H̱olon, Israel\|Sheba Medical Center, Ramat Gan, Israel Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 500 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Survival
NCT04871815	Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.	Completed	Phase 2\|Phase 3	Apr/27/2021	Mar/07/2022
Alternative id - CSI-COVID-19_009 Interventions - Drug: sodium pyruvate nasal spray Study type - Interventional Study results - Has Results Locations - Missouri State University, Springfield, Missouri, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 22 Age - 18 Years to 40 Years (Adult) Outcome measures - Change in the Symptoms of Long COVID-19 Patients\|Change in Body Temperature in Long COVID-19 Patients\|Change in Pulse Rate in Long COVID-19 Patients\|Change in Blood Oxygenation in Long COVID-19 Patients
NCT04412473	COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits	Recruiting		Apr/30/2020	Jun/01/2021
Alternative id - 7837 Interventions - Study type - Observational Study results - No Results Available Locations - Service Médecine Intensive et Réanimation, Strasbourg, France Study designs - Observational Model: Case-Only\|Time Perspective: Retrospective Enrollment - 1000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19
NCT04402814	IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.	Recruiting		May/05/2020	Dec/01/2020
Alternative id - IgG/IgM COVID19\|2005801 Interventions - Diagnostic Test: Clungene rapid test cassette Study type - Observational Study results - No Results Available Locations - Fadi A. Haddad MD Inc., La Mesa, California, United States\|Sharp Grossmont Hospital, La Mesa, California, United States\|Sharp Memorial Hosptial, San Diego, California, United States Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 90 Age - 18 Years and older (Adult, Older Adult) Outcome measures - IgG/IgM antibodies
NCT04749121	Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators	Completed	Not Applicable	Apr/01/2020	Feb/05/2021
Alternative id - 059/63 Interventions - Device: UVC Irradiation\|Drug: UVC Irradiation\|Device: Fit test\|Device: Tensile strength Study type - Interventional Study results - No Results Available Locations - Faculty of Medicine ,Vajira hospital,Navamindradhiraj University, Bangkok, Thailand Study designs - Allocation: N/A\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 20 Age - 18 Years to 60 Years (Adult) Outcome measures - Fit test\|Colony count of microorganisms\|Load of Tensile strength
NCT04406181	Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic	Recruiting	Not Applicable	May/18/2020	Jan/01/2021
Alternative id - COVID-19 Cardiac psy wellbeing Interventions - Behavioral: HADS\|Behavioral: a survey Study type - Interventional Study results - No Results Available Locations - universitair Ziekenhuis Brussel, Jette, Vlaams Brabant, Belgium Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 200 Age - 18 Years to 90 Years (Adult, Older Adult) Outcome measures - Anxiety/depression by means of Hospital Anxiety and Depression Scale (HADS)\|Medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit\|Reduced access to medical and psychological help
NCT04447144	Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome	Recruiting		Jun/01/2020	Sep/01/2020
Alternative id - 1003 Interventions - Study type - Observational Study results - No Results Available Locations - Faculty of Medicine Cairo University, Cairo, Egypt Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 200 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Western versus Mediterranean diet in COVID-19 outcome\|Gut- Lung axis in COVID-19\|Protective role of minerals and vitamins in COVID-19 patients\|non-communicable diseases and COVID-19
NCT04349540	Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19	Active, not recruiting		Apr/15/2020	Jan/15/2021
Alternative id - 20BO08 Interventions - Other: no intervention Study type - Observational Study results - No Results Available Locations - Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom Study designs - Observational Model: Case-Only\|Time Perspective: Prospective Enrollment - 40 Age - 3 Months and older (Child, Adult, Older Adult) Outcome measures - Comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement\|Overall survival at 30 and 100 days after development of oxygen requirement\|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression\|Proportion of patients requiring mechanical ventilation\|Incidence of secondary HLH (as defined by HS score)
NCT04346979	Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation	Not yet recruiting	Not Applicable	Aug/01/2020	Nov/01/2020
Alternative id - 0001 Interventions - Other: Telerehabilitation-Based\|Other: Video-Based Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 50 Age - 45 Years to 65 Years (Adult, Older Adult) Outcome measures - The Brief Resilience Scale\|Nottingham Health Profile\|Mindful Attention Awareness Scale\|The Body Awareness Questionnaire\|Richard-Campbell Sleep Questionnaire\|Lateral bridge test\|Functional reach test\|Beck Depression Scale
NCT04814914	An Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or K032-120	Completed		Mar/25/2021	May/28/2021
Alternative id - K034-120 Interventions - Other: KB109 + Self Supportive Care\|Other: Self Supportive Care (SSC) Alone Study type - Observational Study results - No Results Available Locations - HealthStar Research, LLC, Hot Springs, Arkansas, United States\|Quad Clinical Research, Chicago, Illinois, United States Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 333 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study.
NCT04579627	Facial Hair, PPE and COVID-19	Completed		May/14/2020	Jun/08/2020
Alternative id - 283609 Interventions - Behavioral: Questionnaire Study type - Observational Study results - No Results Available Locations - Royal Cornwall Hospital, Truro, Cornwall, United Kingdom Study designs - Observational Model: Cohort\|Time Perspective: Cross-Sectional Enrollment - 358 Age - Child, Adult, Older Adult Outcome measures - Change in facial hair between January 2020 and during April 2020.\|Does facial hair change adhere to the PPE guidance from PHE
NCT04805216	Covid-19 Vaccine Response in Immunocompromised Haematology Patients	Active, not recruiting		Mar/15/2021	Jul/31/2022
Alternative id - 3025 Interventions - Procedure: Blood test Study type - Observational Study results - No Results Available Locations - University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom Study designs - Observational Model: Other\|Time Perspective: Prospective Enrollment - 75 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in Anti-SARS-COV2 IgG antibodies in immunocompromised haematology patients compared to immunocompetent controls over a 4 month period\|Duration of Anti-SARS-COV2 IgG antibody response in immunocompromised haematology patients compared to immunocompetent controls over a 4 month period\|Correlation in antibody response with patient gender\|Correlation in antibody response with patient ethnicity\|Correlation in antibody response with patient haematological disorder\|Correlation in antibody response with patient age\|Correlation in antibody response with patient treatment\|Correlation in antibody response with patient Covid-19 vaccine type\|Correlation in antibody response with patient pre-vaccine immunological parameters\|Adverse events associated with the first and second dose of a Covid-19 vaccination, reported by the study group and control group\|PCR positive Covid-19 infections reported by the study group and control group\|T-Cell response after second dose Covid-19 vaccination in immunocompromised haematology patients compared to immunocompetent controls over a 4 month period\|Duration of T-Cell response after second dose Covid-19 vaccination in immunocompromised haematology patients compared to immunocompetent controls over a 4 month period
NCT04368676	Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness During the COVID-19 Pandemic	Active, not recruiting	Early Phase 1	Jun/25/2020	Jun/30/2022
Alternative id - 115855 Interventions - Other: Sudarshan Kriya Yoga (SKY)\|Other: Health Enhancement Program Study type - Interventional Study results - No Results Available Locations - London Health Sciences Centre, London, Ontario, Canada Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years to 70 Years (Adult, Older Adult) Outcome measures - Rate of participant recruitment\|Rate of retention\|Completeness of data entry\|Cost of interventions\|Unexpected costs\|Change in Athens Insomnia Scale\|Change in Generalized Anxiety Disorder 7-item scale\|Change in Patient Health Questionnaire 9\|Change in Connor-Davidson Resilience Scale
NCT05012787	A Study of Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases	Not yet recruiting	Phase 3	Sep/13/2021	Dec/16/2022
Alternative id - CLO-SCB-2019-005 Interventions - Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccine\|Biological: Havrix\|Other: Placebo; 0.9% saline Study type - Interventional Study results - No Results Available Locations - Brandwag, Bloemfontein, Brandwag, Bloemfontein, South Africa\|Cape Town, Cape Town, South Africa\|Kyiv, Kyiv, Ukraine\|Kyiv, Kyiv, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Prevention Enrollment - 300 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Percentage of Participants With Unsolicited Adverse Events (AEs)\|Percentage of Participants With Medically Attended AEs (MAAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)\|Percentage of Participants With Any Confirmed Relapse of Immune-mediated Disease (RA, IBD, or RRMS)\|Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody (nAb)\|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb\|Number of Participants With Seroconversion for SARS-CoV-2 nAb\|Geometric Mean Titer (GMT) of SCB-2019 Binding Antibody\|Geometric Mean Fold Rise (GMFRs) of SCB-2019 Binding Antibody\|Number of Participants With Seroconversion for SCB-2019 Binding Antibody\|Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody (nAb) in Participants With RA, IBD, and RRMS\|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb in Participants With RA, IBD, and RRMS\|Number of Participants With Seroconversion for SARS-CoV-2 nAb in Participants With RA, IBD and RRMS\|Geometric Mean Titer (GMT) of SCB-2019 Binding Antibody in Participants With RA, IBD, and RRMS\|Geometric Mean Fold Rise (GMFRs) of SCB-2019 Binding Antibody in Participants With RA, IBD, and RRMS\|Number of Participants With Seroconversion for SCB-2019 Binding Antibody in Participants With RA, IBD, and RRMS\|Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody (nAb) in Participants Who Receive Corticosteroids\|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb in Participants Who Receive Corticosteroids\|Number of Participants With Seroconversion for SARS-CoV-2 nAb in Participants Who Receive Corticosteroids\|Geometric Mean Titer (GMT) of SCB-2019 Binding Antibody in Participants Who Receive Corticosteroids\|Geometric Mean Fold Rise (GMFRs) of SCB-2019 Binding Antibody in Participants Who Receive Corticosteroids\|Number of Participants With Seroconversion for SCB-2019 Binding Antibody in Participants Who Receive Corticosteroids\|Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody (nAb) in Participants Who Receive Tumor Necrosis Factor (TNF)-alpha Inhibitors\|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb in Participants Who Receive TNF-alpha Inhibitors\|Number of Participants With Seroconversion for SARS-CoV-2 nAb in Participants who Received TNF-alpha Inhibitors\|Geometric Mean Titer (GMT) of SCB-2019 Binding Antibody in Participants Who Receive TNF-alpha Inhibitors\|Geometric Mean Fold Rise (GMFRs) of SCB-2019 Binding Antibody in Participants Who Receive TNF-alpha Inhibitors\|Number of Participants With Seroconversion for SCB-2019 Binding Antibody in Participants Who Receive TNF-alpha Inhibitors\|Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody (nAb) in Participants Who Receive Immunomodulators\|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb in Participants Who Receive Immunomodulators\|Number of Participants With Seroconversion for SARS-CoV-2 nAb in Participants who Receive Immunomodulators\|Geometric Mean Titer (GMT) of SCB-2019 Binding Antibody in Participants Who Receive Immunomodulators\|Geometric Mean Fold Rise (GMFRs) of SCB-2019 Binding Antibody in Participants Who Receive Immunomodulators\|Number of Participants With Seroconversion for SCB-2019 Binding Antibody in Participants Who Receive Immunomodulators\|Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody (nAb) in Participants Who Receive Other Treatment Regimens\|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb in Participants Who Receive Other Treatment Regimens\|Number of Participants With Seroconversion for SARS-CoV-2 nAb in Participants Who Receive Other Treatment Regimens\|Geometric Mean Titer (GMT) of SCB-2019 Binding Antibody in Participants Who Receive Other Treatment Regimens\|Geometric Mean Fold Rise (GMFRs) of SCB-2019 Binding Antibody in Participants Who Receive Other Treatment Regimens\|Number of Participants With Seroconversion for SCB-2019 Binding Antibody in Participants Who Receive Other Treatment Regimens\|Number of Participants With Local and Systemic Solicited AEs
NCT04498507	Psychosocial Outcomes in Families of COVID-19 ICU Patients	Completed		Apr/16/2020	Oct/30/2020
Alternative id - Family COVID Interventions - Diagnostic Test: HADS questionnaire Study type - Observational Study results - No Results Available Locations - University Hospital of Liège, Liège, Belgium Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 39 Age - 18 Years and older (Adult, Older Adult) Outcome measures - occurence of anxiety and depression\|occurence of acute stress\|occurence of post-traumatic stress disorder\|quality of life
NCT04886414	Home-based Care and Hand Hygiene Interventions in Honduras	Not yet recruiting	Not Applicable	Sep/01/2021	Sep/01/2022
Alternative id - 2021P001143 Interventions - Other: Phone-based monitoring\|Other: In-person monitoring\|Other: Oxygen saturation monitoring\|Other: Alcohol-based hand sanitizer Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Health Services Research Enrollment - 1647 Age - 21 Years and older (Adult, Older Adult) Outcome measures - Disposition after referral\|Duration of hospitalization\|Duration of ICU and/or ventilator requirement\|Mortality
NCT04454606	The New Silicone N99 Half-Piece Respirator	Completed	Not Applicable	May/01/2020	May/31/2020
Alternative id - 053/2563 Interventions - Device: Fit test\|Device: Filtration Test Study type - Interventional Study results - No Results Available Locations - Bangkok Metroplitan Administration and Vajira Hospital, Bangkok, Thailand Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 43 Age - 18 Years to 60 Years (Adult) Outcome measures - Fit test
NCT04322188	An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications	Completed		Mar/19/2020	May/08/2020
Alternative id - v 2 22nd April 2020 Interventions - Study type - Observational Study results - No Results Available Locations - ASST - Papa Giovanni XXIII, Bergamo, Italy Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 220 Age - 18 Years and older (Adult, Older Adult) Outcome measures - mortality in siltuximab treated patients\|the need of invasive ventilation in siltuximab patients Reduction of the need of time of ventilatory support\|clinical course of patients treated with siltuximab Percentage of patients that undergo to tracheostomy\|Safety Improvement of the lung function assessed by radiologic findings\|the effect on inflammatory parameters\|Correlation of outcomes with IL-6 levels
NCT04391400	The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines	Not yet recruiting		Jun/01/2020	Jun/30/2021
Alternative id - IVS-000-002 Interventions - Diagnostic Test: nasal pharyngeal (NP) swab samples\|Diagnostic Test: peripheral blood draw Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Case-Only\|Time Perspective: Prospective Enrollment - 500 Age - Child, Adult, Older Adult Outcome measures - Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines
NCT04872751	Immune Response of Haemodialysis Patients Post Covid-19 Vaccination	Recruiting		Apr/27/2021	Apr/01/2022
Alternative id - NMRR-21-634-59445 Interventions - Study type - Observational Study results - No Results Available Locations - Penang Hospital, George Town, Penang, Malaysia Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 425 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change From Baseline in post vaccination SARS-CoV-2 neutralizing antibody level\|Change From Baseline in post vaccination SARS-CoV-2 neutralizing antibody level after 1st inoculation of the vaccine (incomplete vaccination)
NCT04954651	Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines	Recruiting		Jul/07/2021	Feb/28/2022
Alternative id - 99-25/2/2021 Interventions - Biological: Approved vaccines against Sars-Cov2 Study type - Observational Study results - No Results Available Locations - University Hospital of Patras, Patras, Greece Study designs - Observational Model: Other\|Time Perspective: Prospective Enrollment - 1000 Age - Child, Adult, Older Adult Outcome measures - Antibody titer against Sars-Cov2
NCT04900389	The Effect of Nurses' Having COVID-19 on Their Professional Lives	Not yet recruiting		May/15/2021	Oct/15/2021
Alternative id - 2021-4/49 Interventions - Study type - Observational Study results - No Results Available Locations - Bursa Uludag University Faculty of Health Sciences, Bursa, Turkey Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 354 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Anxiety levels of nurses according to their COVID-19 passing status\|Wise awareness levels of nurses based on their COVID-19 passing status
NCT04621084	Influence of the COVId-19 Pandemic on STRESS and Eating Habits	Recruiting		Apr/01/2020	Dec/31/2025
Alternative id - 2020 COVISTRESS NUTRITION Interventions - Behavioral: Eating habits Study type - Observational Study results - No Results Available Locations - Clermont-Ferrand University Hospital, clermont-Ferrand, Aura, France Study designs - Observational Model: Cohort\|Time Perspective: Cross-Sectional Enrollment - 1000 Age - 10 Years and older (Child, Adult, Older Adult) Outcome measures - Stress measures\|Nutrition
NCT04890652	Digital Interventions to Treat Hazardous Drinking	Recruiting	Not Applicable	Oct/13/2021	Aug/31/2023
Alternative id - 2000026333\|R01AA026844-02S1 Interventions - Behavioral: 4-week intervention Study type - Interventional Study results - No Results Available Locations - Yale University, New Haven, Connecticut, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 40 Age - 18 Years to 55 Years (Adult) Outcome measures - Change in alcohol use (quantity)\|Change in alcohol use (frequency)
NCT04427267	Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients	Completed		Jun/03/2020	Jun/27/2020
Alternative id - PPE-02 Interventions - Other: Personal protective equipment from biological hazard Study type - Observational Study results - No Results Available Locations - Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 6 Age - 18 Years to 45 Years (Adult) Outcome measures - Skin thermometry\|Hygrometry under costume\|Heart rate\|Air thermometry\|Air hygrometry
NCT04564040	A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole	Completed	Phase 1	Oct/12/2020	Dec/11/2020
Alternative id - D8223C00005 Interventions - Drug: Acalabrutinib Treatment A\|Drug: Acalabrutinib Treatment B\|Drug: Acalabrutinib Treatment C\|Drug: Acalabrutinib Treatment D Study type - Interventional Study results - No Results Available Locations - Research Site, Berlin, Germany Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 20 Age - 18 Years to 55 Years (Adult) Outcome measures - Part 1 and 2: Area under plasma concentration-time curve from time zero to infinity (AUCinf)\|Part 1 and 2: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)\|Part 1 and Part 2: Maximum observed plasma concentration (Cmax)\|Part 1 and Part 2: Area under the plasma concentration-time curve from time zero to 24 hours post dose (AUC0-24)\|Part 1 and 2: Time to reach maximum observed plasma concentration (tmax)\|Part 1 and 2: Half-life associated with terminal slope (λz) of a semi-logarithmic concentrationtime curve (t1/2)\|Part 1 and 2: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)\|Part 1 and 2: Terminal elimination rate constant (λz)\|Part 1 and 2: Apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (CL/F)\|Part 1 and 2: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz/F)\|Part 1 and 2: Metabolite to parent ratio based on AUCinf and/or AUClast (M:P[AUC])\|Part 1 and 2: Metabolite to parent ratio based on Cmax (M:P[Cmax])\|Number of subjects with serious and non-serious adverse events
NCT04845191	COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines	Withdrawn	Phase 1\|Phase 2	Dec/01/2021	Aug/01/2022
Alternative id - COVID-4.009 Interventions - Biological: hAd5-S-Fusion+N-ETSD vaccine Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Phase 1 Safety: Incidence of MAAEs and SAEs\|Phase 1 Safety: Incidence and severity of solicited local reactogenicity AEs\|Phase 1 Safety: Incidence and severity of solicited systemic reactogenicity AEs\|Phase 1 Safety: Incidence and severity of unsolicited AEs\|Phase 1 Safety: Incidence of changes of laboratory safety examinations\|Phase 1 Safety: Vital Sign - Temperature\|Phase 1 Safety: Vital Sign - Heart Rate\|Phase 1 Safety: Vital Sign - Blood Pressure\|Phase 1 Safety: Vital Sign - Respiratory Rate\|Phase 2 Efficacy: Percent of subjects that show an increase in N-reactive T cells\|Phase 1 Humoral Immunogenicity: GMT of S-specific and N-specific antibodies\|Phase 1 Humoral Immunogenicity: GMT of neutralizing antibody\|Phase 1 Mucosal Immunogenicity: GMT of IgA antibody levels\|Phase 1 Cellular Immunogenicity: T cell activity\|Phase 2 Efficacy: Incidence and severity of COVID-19 ≥14 days after vaccination\|Phase 2 Efficacy: Mean SARS-CoV-2 viral load\|Phase 2 Efficacy: Humoral Immunogenicity - GMT of S-specific and N-specific antibodies\|Phase 2 Efficacy: Humoral Immunogenicity - GMT of neutralizing antibody\|Phase 2 Efficacy: Mucosal Immunogenicity - GMT of IgA antibody levels\|Phase 2 Efficacy: Cellular Immunogenicity - T cell activity\|Phase 2 Safety: Incidence of MAAEs and SAEs\|Phase 2 Safety: Incidence and severity of solicited local reactogenicity AEs\|Phase 2 Safety: Incidence and severity of solicited systemic reactogenicity AEs\|Phase 2 Safety: Incidence and severity of unsolicited AEs\|Phase 2 Safety: Incidence of changes of laboratory safety examinations\|Phase 2 Safety: Vital Sign - Temperature\|Phase 2 Safety: Vital Sign - Heart rate\|Phase 2 Safety: Vital Sign - Blood Pressure\|Phase 2 Safety: Vital Sign - Respiratory rate
NCT04601415	Point of Care Artificial Intelligence Tool for Heart Failure Diagnosis	Recruiting		Feb/01/2021	Oct/01/2022
Alternative id - 285417 Interventions - Diagnostic Test: ECG from handheld device Study type - Observational Study results - No Results Available Locations - Patrik Bachtiger, London, Non-US/Non-Canadian, United Kingdom Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 1500 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Area under receiver operating curve
NCT04847622	Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.	Recruiting		Feb/01/2021	Jun/30/2021
Alternative id - NEAT ID 909REM Interventions - Drug: Remdesivir Study type - Observational Study results - No Results Available Locations - CHU de Nantes, Nantes, France\|Hospital Lariboisiere, Paris, France\|Hopital Saint-Louis, Paris, France\|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel\|Erasmus Medical Center, Rotterdam, Netherlands\|Hospital Germans Trias i Pujol, Barcelona, Spain\|Hospital Clínic de Barcelona, Barcelona, Spain\|Hospital Universitari Vall d'Herbon, Barcelona, Spain\|Hospital Clinico Universitario San Carlos, Madrid, Spain\|Hospital Universitario 12 de Octubre, Madrid, Spain\|Royal Free Hospital, London, United Kingdom\|Chelsea & Westminster Hospital, London, United Kingdom Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 450 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Clinical status assessed by a 7-point ordinal scale\|Proportion of clinical improvement.\|Severity of disease\|Time to SpO2\|Duration of oxygen therapy\|Admission to the Intensive Care Unit\|Time on mechanical ventilation/ECMO\|Duration of hospitalisation
NCT04516668	Effect of Tele-consultation in Addition With Psychiatric Follow-up During COVID-19 in Women Who Have Medical History of Post-partum Depression	Not yet recruiting		Nov/01/2020	Nov/01/2020
Alternative id - APHP200878 Interventions - Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 250 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Evaluation of Hospital anxiety and depression scale (HAD)\|Evaluation of Edinburgh Postpartum Depression Scale (EPDS)\|Evaluation of HAD score in fathers\|Evaluation of EPDS in fathers\|Study of the relationship between maternals and paternals symptoms\|Study of difficuties in child during the quarantine\|Risk and protection factors
NCT04342104	NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure	Recruiting		Apr/01/2020	Nov/15/2021
Alternative id - 08-04-2020 Interventions - Other: Monitoring for aggravation\|Other: Evaluate HACOR score effectivity in this patients Study type - Observational Study results - No Results Available Locations - Hospital General Universitario Morales Meseguer, Murcia, Spain Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - HACOR score efficacy\|HACOR score addaptation
NCT04357847	Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection	Recruiting		Apr/09/2020	Aug/31/2021
Alternative id - 2020/097/OB Interventions - Study type - Observational Study results - No Results Available Locations - Rouen University Hospital, Rouen, France Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality\|Association of Endothelin-1 plasma level with 28 days mortality\|Association of Vascular Endothelial Growth Factor A plasma level with 28 days mortality\|Association of soluble Vascular Endothelial Growth Factor Receptor type 1 with 28 days mortality\|Association of syndecan -1 plasma level with 28 days mortality\|Association of D-dimers plasma levels with thrombotic events\|Association of von Willebrandt Factor with thrombotic events\|Association of Viscoelastic testing with thrombotic events
NCT04765540	The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh	Completed	Not Applicable	Jan/03/2021	May/06/2021
Alternative id - 2020091 Interventions - Behavioral: Low Intensity Nudges\|Behavioral: High Intensity Activities\|Behavioral: BRAC's business-as-usual Study type - Interventional Study results - No Results Available Locations - BRAC, Dhaka, Bangladesh\|BRAC Khulna, Khulna, Bangladesh\|BRAC Mymensingh, Mymensingh, Bangladesh Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 855 Age - Child, Adult, Older Adult Outcome measures - Average handwashing station soap pedal presses per day (in weeks 1 to 3)\|Average handwashing station soap pedal presses per day (in weeks 4 to 6)
NCT04909892	Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise	Withdrawn	Phase 2	Aug/01/2021	Jan/01/2022
Alternative id - MSC-PLH-201 Interventions - Biological: COVI-MSC Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in 6-Minute Walk Distance (6MWD) at Day 60\|Change in 6MWD at Day 30\|Change in Pulmonary Function Tests (PFTs)\|Change in oxygenation\|Change in biomarker levels
NCT04854772	Mind Body Intervention for COVID-19 Long Haul Syndrome	Recruiting	Not Applicable	May/15/2021	Aug/01/2022
Alternative id - 2021P-000336 Interventions - Behavioral: Mind Body Syndrome Therapy for Long Covid Study type - Interventional Study results - No Results Available Locations - Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 22 Age - 18 Years to 60 Years (Adult) Outcome measures - Change in somatic symptom severity\|Average Pain\|Pain intensity\|Pain Bothersomeness\|Pain-related Anxiety\|Fatigue\|Dyspnea\|Brain Fog
NCT04815850	Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study	Recruiting		Mar/01/2021	Dec/31/2021
Alternative id - 0810 Interventions - Study type - Observational Study results - No Results Available Locations - University Hospital Leicester NHS Trust, Leicester, Leicestershire, United Kingdom Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 150 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in COVID-19 IgG antibody (RLU)
NCT04322786	The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?	Unknown status		Jan/01/1998	Mar/31/2021
Alternative id - ISAC17_205R Interventions - Drug: ACE inhibitor Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 1302508 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Incidence of influenza
NCT04734561	Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease	Completed	Not Applicable	Feb/08/2021	Sep/29/2021
Alternative id - 20/715-E_BS Interventions - Other: Inspiratory muscle training group\|Other: Inspiratory muscle training placebo group\|Other: Inspiratory + expiratory muscle training group\|Other: Inspiratory + expiratory muscle training placebo group Study type - Interventional Study results - No Results Available Locations - UComplutenseMadrid, Madrid, Spain Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 88 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Health-related quality of life\|Exercise tolerance\|Maximum respiratory pressures\|Inspiratory muscle endurance\|Upper limb muscle strength\|Lung function (forced spirometry)\|Cognitive factors\|Lower limb muscle strength\|Psychological factors
NCT04403438	Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic	Enrolling by invitation		Apr/01/2020	Jun/15/2020
Alternative id - 10840098-604.01.01-E.14697 Interventions - Other: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. Study type - Observational Study results - No Results Available Locations - IstanbulU, Istanbul, Bakırköy, Turkey Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 45 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - IPAQ-SF\|Numeric Rating Scale\|Short-Form 36 Health Survey (SF-36)\|Exercise Stage of Change Questionnaire\|Exercise Self-Efficacy Questionnaire\|Decisional Balance Questionnaire
NCT04992247	Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise	Not yet recruiting	Phase 2	Jul/01/2022	Sep/01/2023
Alternative id - MSC-PLH-201BR Interventions - Biological: COVI-MSC\|Biological: Placebo Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in 6-Minute Walk Distance (6MWD) at Day 60\|Change in 6MWD at Day 30\|Relief of symptoms on Day 30 and Day 60\|Change in Pulmonary Function\|Change in oxygenation\|Change in biomarker levels
NCT05107271	Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease	Not yet recruiting		Nov/15/2021	Mar/15/2023
Alternative id - 2021-5859 Interventions - Diagnostic Test: COVID-19 serosurvey Study type - Observational Study results - No Results Available Locations - Postgraduate Institute of Medical Education and Research, Chandigarh, Choose Any State/Province, India\|PGIMER, Chandigarh, India Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 300 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Long haul COVID-19 related symptoms\|Immunogenicity of vaccine
NCT04753645	BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition	Active, not recruiting	Not Applicable	Sep/19/2020	May/01/2021
Alternative id - BIGD2021 Interventions - Behavioral: Handwashing stations at the public places and no soap\|Behavioral: No activities of the HBCC project and also no soap (Pure Control)\|Behavioral: Soap distributed but no activities of the HBCC project\|Behavioral: HBCC project and Soap Study type - Interventional Study results - No Results Available Locations - BRAC, Bangladesh, Dhaka, Bangladesh Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 3840 Age - 10 Years and older (Child, Adult, Older Adult) Outcome measures - Daily handwashing frequency\|Likelihood of using soap when handwashing\|Prevalence of transmissible diseases in the past 15 days\|Knowledge of handwashing practices\|Attitudes\|Handwashing at the public places\|Mask usage
NCT04367740	ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19	Enrolling by invitation		Apr/28/2020	Dec/01/2022
Alternative id - 20-0937 Interventions - Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2 Study type - Observational Study results - No Results Available Locations - Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States Study designs - Observational Model: Case-Only\|Time Perspective: Cross-Sectional Enrollment - 10000 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection.\|Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection.
NCT04732468	COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA	Active, not recruiting	Phase 1	Feb/24/2021	Apr/01/2022
Alternative id - COVID-4.005 Interventions - Biological: hAd5-S-Fusion+N-ETSD (Suspension for injection)\|Drug: hAd5-SFusion+ N-ETSD (Oral capsule) Study type - Interventional Study results - No Results Available Locations - Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States\|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 26 Age - 18 Years to 55 Years (Adult) Outcome measures - Incidence of MAAEs and SAEs\|Incidence and severity of solicited local reactogenicity AEs\|Incidence and severity of solicited systemic reactogenicity AEs\|Incidence and severity of unsolicited AEs\|Incidence of changes of laboratory safety examinations\|Vital Sign - Temperature\|Vital Sign - Heart rate\|Vital Sign - Blood Pressure\|Vital Sign - Respiratory Rate\|GMFR in IgG titer\|GMT of S-specific, RBD-specific, and N-specific antibodies\|Percentage of subjects who seroconverted\|GMFR in neutralizing antibody\|GMT of neutralizing antibody\|Seroconversion rate of neutralizing antibody\|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein\|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein
NCT05062473	Utilizing Telemedicine for Hypertension Treatment Lifestyle Modification in Central Harlem	Recruiting	Not Applicable	Oct/04/2021	Oct/01/2022
Alternative id - 20-10022836\|1 T1NHP391850100. Interventions - Behavioral: Lifestyle Modification Webinars Focused on Hypertension Control Study type - Interventional Study results - No Results Available Locations - Weill Cornell Medicine, New York, New York, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Participant's Satisfaction with the Curriculum at 12 Weeks\|Change in Number of Participants Virtually Attending the Health Education Seminars\|Change in Participant's Rate of Completion of Weekly Blood Pressure Recordings\|Change in Participant's Rate of Completion of Weekly Steps Recordings\|Mean Change in Systolic Blood Pressure Measurement.\|Mean Change in Diastolic Blood Pressure Measurement.\|Mean Change in Number of Daily Steps Measured by Pedometer.\|Change in Self-Reported Health Attitudes and Behaviors As Assessed by Survey.
NCT05074875	COVID-19 Respiratory Outcomes Registry	Recruiting		Jan/15/2021	Dec/01/2023
Alternative id - 20-05022161 Interventions - Other: Questionnaires and Patient Reported Outcomes (PROs)\|Diagnostic Test: Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)\|Genetic: Blood Samples for Biomarkers\|Diagnostic Test: High Resolution Computed Tomography\|Diagnostic Test: Physical Exam and Vital Signs\|Diagnostic Test: Medical Research Council Sum Score\|Diagnostic Test: Hand Grip Strength\|Diagnostic Test: Spirometry\|Diagnostic Test: Diffusing Capacity of Carbon Monoxide\|Diagnostic Test: 6 Minute Walk Test\|Diagnostic Test: Sit to Stand (STS) Measurement Study type - Observational Study results - No Results Available Locations - Washington University of St. Louis, Saint Louis, Missouri, United States\|New York University Langone Medical Center, New York, New York, United States\|Weill Cornell Medicine, New York, New York, United States\|Baylor College of Medicine, Houston, Texas, United States Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 300 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in fibrotic and non-fibrotic interstitial opacities on chest HRCT at 48 weeks after hospitalization for COVID-19 or outpatient COVID-19 infections which require treatment with supplemental oxygen\|Changes from baseline and evidence of disease progression seen on high resolution computed tomography\|Changes from baseline and evidence of disease progression on pulmonary function testing\|Changes from baseline and evidence of disease progression seen on pulmonary function testing\|Changes from baseline and evidence of disease progression see on pulmonary function testing\|Changes from baseline and evidence of disease progression via 6 Minute Walk Test\|Change in pre- and post- six minute walk test Borg Scale Dyspnea score from baseline and at 12, 24, and 48 weeks.\|Change in pre- and post- six minute walk test Borg Scale Fatigue score from baseline and at 12, 24, and 48 weeks.\|Changes from baseline and evidence of disease progression by Hand Grip Strength\|Changes from baseline and evidence of disease progression per the Quality of Life reported outcomes. EuroQol-5D (EQ-5D)\|Changes from baseline and evidence of disease progression per the Quality of Life reported outcomes. St. George's Respiratory Questionnaire (SGRQ)\|Changes from baseline and evidence of disease progression per the Quality of Life reported outcomes. Generalized Anxiety 7-Item (GAD-7)\|Changes from baseline and evidence of disease progression per the Quality of Life reported outcomes. Patient Health Questionnaire 9 (PHQ-9)\|Changes from baseline and evidence of disease progression per the Quality of Life reported outcomes- Impact of Events Scale Revised (IES-R)\|Changes from baseline and evidence of disease progression per the Quality of Life reported outcomes- PROMIS-29 + 2 Profile\|Examine the effects of COVID-19 on the presence of molecular biomarkers associated with Interstitial Lung Disease
NCT04632355	Musculoskeletal Pain in Patients With Covid-19 Who Have Hospital Care	Not yet recruiting		Dec/01/2020	Jul/31/2021
Alternative id - Covid19-Pain Interventions - Other: Interview Study type - Observational Study results - No Results Available Locations - Jorge Hugo Villafañe, Milan, Italy Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs\|PainDETEC\|EuroQol-5D\|The Hospital Anxiety and Depression Scale
NCT05197153	A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19	Not yet recruiting	Phase 2	Jan/01/2022	Dec/01/2022
Alternative id - CT-COV-24 Interventions - Biological: Half dose of MVC-COV1901\|Biological: Full dose of MVC-COV1901\|Biological: AZD1222\|Biological: Half dose of mRNA-1273 Study type - Interventional Study results - No Results Available Locations - Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan\|National Taiwan University Hospital, Taipei, Taiwan\|Taipei Municipal Wan Fang Hospital, Taipei, Taiwan\|Taipei Veteran General Hospital, Taipei, Taiwan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Prevention Enrollment - 960 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Incidence of Adverse Events from Day 1 to 28\|Primary Immunogenicity-1\|Primary Immunogenicity-2\|Primary Immunogenicity-3\|Primary Immunogenicity-4\|Incidence of Adverse Events from Day 1 to 181\|Secondary Immunogenicity (Humoral)-1\|Secondary Immunogenicity (Humoral)-2\|Secondary Immunogenicity (Humoral)-3\|Secondary Immunogenicity (Cellular)
NCT04898738	Prospective COVID-19 Cohort Study, Dominican Republic	Not yet recruiting	Not Applicable	Aug/01/2021	Sep/01/2022
Alternative id - 2021p001294 Interventions - Other: Alcohol based hand sanitizer Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 2000 Age - 2 Years and older (Child, Adult, Older Adult) Outcome measures - Hand hygiene practices\|Acceptability of hand hygiene technology\|SARS-Cov-2 seroconversion
NCT05274685	Early Renal Replacement Therapy in COVID 19 Patients With AKI Does it Improve the Outcome?	Completed	Not Applicable	Jun/01/2021	Jan/01/2022
Alternative id - soh-Med-22-2-24 Interventions - Procedure: haemodialysis Study type - Interventional Study results - No Results Available Locations - Faculty of Medicine, Sohag University, Sohag, Egypt Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - reduction of Sequential Organ Failure Assessment Score
NCT04930731	Risk Factors and Characteristics of COVID 19 Infection in Patients With Haematological Diseases	Not yet recruiting		Sep/01/2021	Sep/01/2022
Alternative id - COVID 19 &haematological pts Interventions - Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 60 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Risk Factors and Characteristics of COVID 19 infection in Patients with Haematological Diseases
NCT04602832	Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19	Enrolling by invitation	Not Applicable	Oct/14/2020	Dec/01/2020
Alternative id - University of British Columbia Interventions - Other: Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19 Study type - Interventional Study results - No Results Available Locations - University of British Columbia, Kelowna, British Columbia, Canada Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 350 Age - 19 Years and older (Adult, Older Adult) Outcome measures - Beck Depression Inventory - II (BDI-II)\|Satisfaction With Life Scale (SWLS)\|Generalized Anxiety Disorder - 7 (GAD-7)\|Patient Health Questionnaire (PHQ-9)\|Perceived Stress Scale (PSS)\|Positive and Negative Affect Scale (PANAS)\|Health Anxiety Inventory Short-Form (HAI-SF)\|World Health Organization Quality of Life (WHOQOL - BREF)\|Meaning In Life Questionnaire (MLQ)\|Sleep Disorder Questionnaire (SDQ)\|Measure of Attachment Qualities (MAQ)\|University of California, Los Angeles Loneliness Scale (UCLA Loneliness Scale)\|Insomnia Severity Index (ISI)\|Paffenbarger Physical Activity Questionnaire (PPAQ)\|PTSD Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (PCL-5)\|European Quality of Life Group - 5 Dimensions - 5 Levels (EQ-5D-5L)
NCT05228899	Zofin to Treat COVID-19 Long Haulers	Not yet recruiting	Phase 1\|Phase 2	Feb/15/2022	Sep/30/2023
Alternative id - 27378 Interventions - Drug: Zofin\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - NewportNativeMD, Newport Beach, California, United States Study designs - Allocation: Randomized\|Intervention Model: Single Group Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 30 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Incidence of Severe Adverse Events\|Fatigue Severity Score Score\|Daily Diary of COVID-19 Related Symptom\|COVID-19 Associated Symptoms Length\|COVID-19 Associated Symptoms Mitigation\|Beck Depression Inventory Score\|Mental Fatigue Questionnaire Score\|Pulse Oxygen Saturation\|Heart Rate Variability by ECG\|Transthoracic echocardiogram\|Frequency of Urgent Care\|C-reactive protein Levels\|D-dimer Levels\|Cytokine Levels
NCT04326036	Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection	Enrolling by invitation	Early Phase 1	Mar/25/2020	Jan/31/2023
Alternative id - GARM COVID19 Interventions - Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)\|Device: Centricyte 1000\|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution\|Drug: Liberase Enzyme (Roche)\|Drug: Sterile Normal Saline for Intravenous Use Study type - Interventional Study results - No Results Available Locations - Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10 Age - 18 Years to 90 Years (Adult, Older Adult) Outcome measures - Incidence of Treatment-Emergent Adverse Events\|Pulmonary Function Analysis\|Digital Oximetry
NCT05074706	Evaluation of the Immune Response to Sars-Cov-2 Vaccines in Haematological Patients: Prospective Single Center Study	Recruiting		Jun/09/2021	Jun/01/2022
Alternative id - Hema-C19-Vax Interventions - Biological: IgG antibodies to Sars-Cov-2\|Biological: QuantiFERON SARS-CoV-2 test Study type - Observational Study results - No Results Available Locations - San Gerardo Hospital, Monza, Lombardia, Italy Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 700 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Rate of seroconversion in hematological patients who received a mRNA SARS-CoV-2 vaccine\|To compare the seroconversion rate in haematological patients versus healthy subjects.\|To correlate the rate of seroconversion in hematological patients to the specific haematological diseases.\|To correlate the rate of seroconversion to previous therapies\|To assess the efficacy of vaccine by estimating how many patients will be infected by SARS-CoV-2 in the 9 months after the administration of the second vaccine dose.\|To analize T-cell response in those patients who will result negative for specific antibodies anti-Sars-Cov-2 after two doses of mRNA SARS-Cov-2 vaccination
NCT04597216	Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix (NanoDx-CoV-19)	Recruiting	Not Applicable	Oct/15/2020	Dec/31/2021
Alternative id - 38RC20.289 Interventions - Device: sample of blood and saliva Study type - Interventional Study results - No Results Available Locations - olivier EPAULARD, Grenoble, France Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Diagnostic Enrollment - 200 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Feasibility of proteomic profile\|Interest of proteomic profile\|Stability of proteomic profile
NCT04704388	Study Project Comparing the Sequelae of COVID-19 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care	Completed		Jun/01/2020	Oct/01/2020
Alternative id - COMEBAC Interventions - Study type - Observational Study results - No Results Available Locations - Bicêtre Hospital, Le Kremlin-Bicêtre, France Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 478 Age - 18 Years and older (Adult, Older Adult) Outcome measures - post-intensive care syndrome (PICS)\|Evaluate the 3-month mortality of patients released alive from intensive care\|Describe the overall state of health and the main organ sequelae of these patients\|functional respiratory sequelae
NCT04894474	A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2	Withdrawn	Phase 2\|Phase 3	Jun/17/2021	Jul/24/2022
Alternative id - 1487-0003\|2021-000408-39 Interventions - Drug: BI 767551 intravenous\|Drug: BI 767551 inhalation\|Drug: Placebo intravenous\|Drug: Placebo inhalation Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - The primary endpoint of this study is symptomatic SARS-CoV-2 infection (RT-qPCR confirmed based on NP swabs, with a score >= 2 on the WHO Clinical Progression Scale) (Cohort A only)\|SARS-CoV-2 infection, with or without symptoms (Cohort A only)\|Asymptomatic SARS-CoV-2 infection (with a score not exceeding 1 on the WHO Clinical Progression Scale) (Cohort A only)\|Severity of COVID-19 (No, mild, moderate, or severe COVID-19, with a maximum score of 0, 1-3, 4-5, or >= 6,respectively, on the WHO Clinical Progression Scale) (Cohort A)\|Severity of COVID-19 (No, mild, moderate, or severe COVID-19, with a maximum score of 0, 1-3, 4-5, or >= 6,respectively, on the WHO Clinical Progression Scale) (Cohort B)\|Hospitalization due to COVID-19 for >= 24 hours (Cohort A)\|Hospitalization due to COVID-19 for >= 24 hours (Cohort B)\|Hospitalization due to COVID-19 for >= 24 hours or death (Cohort A)\|Hospitalization due to COVID-19 for >= 24 hours or death (Cohort B)\|Death (Cohort A)\|Death (Cohort B)
NCT04455815	A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive.	Active, not recruiting	Phase 2	Sep/25/2020	Dec/31/2021
Alternative id - CRUKD/20/002\|2020-002110-41 Interventions - Drug: Camostat Study type - Interventional Study results - No Results Available Locations - Chawton Park Surgery, Alton, United Kingdom\|The University of Edinburgh, Edinburgh, United Kingdom\|Church Avenue Medical Group, Harrogate, United Kingdom\|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom\|Trafalgar Medical Practice, Portsmouth, United Kingdom\|Preston Lantern Centre, Preston, United Kingdom\|Clarence Medical Centre, Rhyl, United Kingdom\|Velindre Cancer Centre, Wales, United Kingdom\|Eynsham Medical Centre, Witney, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - To further assess the safety and toxicity profile of camostat to support integration into a Phase III trial.\|To confirm PK parameter maximum concentration (Cmax) aligns with the established PK profile of camostat (4-(4-Guanidinobenzoyloxy) phenylacetic acid (GBPA)).\|To confirm PK parameter time to maximum concentration (Tmax) aligns with the established PK profile of camostat (4-(4-Guanidinobenzoyloxy) phenylacetic acid (GBPA)).\|To confirm PK parameter area under the concentration time curve (AUC) aligns with the established PK profile of camostat (4-(4-Guanidinobenzoyloxy) phenylacetic acid (GBPA)).\|To confirm PK parameter half-life (T1/2) aligns with the established PK profile of camostat (4-(4-Guanidinobenzoyloxy) phenylacetic acid (GBPA)).\|To assess the ability of camostat to reduce the requirement for COVID-19 related hospital admission in community patients with SARS-CoV-2 infection.\|To evaluate the requirement for supplementary oxygen (non-invasive or mechanical invasive) in patients who have received camostat as treatment for SARS-CoV-2 infection.\|To evaluate the requirement for ventilation in patients who have received camostat as treatment for SARS-CoV-2 infection.\|To evaluate efficacy of camostat by effect on COVID-19 related clinical improvement.
NCT05115084	The Effect of the COVID-19 Epidemic Process on the Nutritional Habits and Body Weights of Adults	Not yet recruiting		Dec/03/2021	Jun/02/2022
Alternative id - 2021/23 Interventions - Other: no intervention Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Case-Only\|Time Perspective: Prospective Enrollment - 160 Age - 19 Years to 70 Years (Adult, Older Adult) Outcome measures - Questionnaire
NCT05049226	Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine	Enrolling by invitation	Phase 2	Sep/24/2021	Sep/01/2023
Alternative id - TVTN001 Interventions - Biological: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose\|Biological: Pfizer/BioNTech BNT162b2 vaccine (PF) full dose\|Biological: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose\|Biological: Pfizer/BioNTech BNT162b2 vaccine (PF) half dose Study type - Interventional Study results - No Results Available Locations - Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand\|Faculty of Medicine Chulalongkorn University, Pathum Wan, Bangkok, Thailand\|Faculty of Medicine Thammasat University, Khlong Luang, Pathum Thani, Thailand\|Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi hospital, Mahidol University, Bang Phli, Samut Prakan, Thailand\|Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand\|Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand\|Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Prevention Enrollment - 1320 Age - 20 Years and older (Adult, Older Adult) Outcome measures - GMT Anti-S IgG at baseline and after vaccination\|GMFR changed from baseline in anti-S IgG GMT after vaccination\|Anti-S IgG Seroresponses changed from baseline after vaccination\|GMT against SARS-Cov-2 pseudovirus (PVNT) Neutralizing antibody titer 50 at baseline and after vaccination\|GMFR changed from baseline in NT50 against SARS-CoV-2 pseudovirus after vaccination\|Frequency of solicited reportable local adverse event after vaccination\|Frequency of solicited reportable systemic adverse event after vaccination\|Frequency of all unsolicited AEs\|Frequency of SAEs\|NT50 GMT against SARS-Cov-2 by micro neutralization assay at baseline and day 28 and day 90 after vaccination\|GMFR changed from baseline in NT50 against SARS-CoV-2 (micro NT Delta/WT NA) at 28 and 90 days after vaccination among those positives by PNT assay\|NT50 seroresponses against SARS-CoV-2 using micro NT changed from baseline at 28 and 90 days after vaccination among those positive by PVNT assay
NCT04375410	Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic	Completed		Apr/22/2020	May/10/2020
Alternative id - SH042020 Interventions - Study type - Observational Study results - No Results Available Locations - Tine Caroc Warner, Hjørring, Nordjylland, Denmark Study designs - Observational Model: Cohort\|Time Perspective: Cross-Sectional Enrollment - 6273 Age - up to 13 Years (Child) Outcome measures - Dermal reaction to frequent hand wash and disinfection in children
NCT04896970	Risk of SARS-CoV-2 Infection (COVID-19) in a Standing Concert in a Closed Performance Hall	Withdrawn	Not Applicable	Jun/01/2021	Jul/01/2021
Alternative id - RECHMPL21_0110 Interventions - Other: Concert Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Health Services Research Enrollment - 0 Age - 18 Years to 59 Years (Adult) Outcome measures - SARS-CoV-2 incidence\|Time to screen all participants
NCT04584658	Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)	Recruiting		Sep/15/2020	Dec/01/2021
Alternative id - 20/NW/0333 Interventions - Diagnostic Test: Fibreoptic Endoscopic Evaluation of Swallowing (FEES)\|Diagnostic Test: Videofluoroscopy\|Other: Dysphagia Handicap Index (DHI)\|Other: Voice Symptom Scale (VoiSS) Study type - Observational Study results - No Results Available Locations - Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 36 Age - 18 Years to 85 Years (Adult, Older Adult) Outcome measures - Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).\|The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months)\|The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only.\|Relationship between severity of dysphonia and/or dysphagia with grade of ARDS\|Relationship between severity of dysphonia and/or dysphagia with length of intubation\|Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation\|Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months.\|Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months
NCT04659889	Clinical and Haematological Phenotypes in Long COVID	Completed		Dec/01/2020	Jun/01/2021
Alternative id - LCV Interventions - Diagnostic Test: Blood sampling (venesection) Study type - Observational Study results - No Results Available Locations - The Physicians' Clinic, London, United Kingdom Study designs - Observational Model: Case-Control\|Time Perspective: Cross-Sectional Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Observation of frequency of abnormal haematological parameters and association with long-Covid clinical phenotypes versus controls.
NCT04939558	Cardiorespiratory Diagnostic Study	Enrolling by invitation		Jun/02/2021	Jun/30/2022
Alternative id - G001-21 Interventions - Device: N-Tidal C handset Study type - Observational Study results - No Results Available Locations - Modality Partnership, Birmingham, West Midlands, United Kingdom Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 740 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Breath records from participants with Chronic Obstructive Pulmonary Disease (COPD)\|Breath records from Healthy volunteers (no previous or current cardiorespiratory diagnoses)\|Breath records from participants with Asthma\|Breath records from participants with Congestive cardiac failure\|Breath records from participants with Anaemia\|Breath records from participants with Bronchiectasis\|Breath records from participants with Lung cancer\|Breath records from participants with Interstitial Lung Disease\|Breath records from participants with Long COVID\|Breath records from participants with Upper airway obstruction disorder
NCT04843722	COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines	Withdrawn	Phase 1\|Phase 2	Dec/01/2021	Aug/01/2022
Alternative id - COVID-4.006 Interventions - Biological: hAd5-S-Fusion+N-ETSD vaccine Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Phase 1 Safety: Incidence of MAAEs and SAEs\|Phase 1 Safety: Incidence and severity of solicited local reactogenicity AEs\|Phase 1 Safety: Incidence and severity of solicited systemic reactogenicity AEs\|Phase 1 Safety: Incidence and severity of unsolicited AEs\|Phase 1 Safety: Incidence of changes of laboratory safety examinations\|Phase 1 Safety: Vital Sign - Temperature\|Phase 1 Safety: Vital Sign - Heart Rate\|Phase 1 Safety: Vital Sign - Blood Pressure\|Phase 1 Safety: Vital Sign - Respiratory Rate\|Phase 2 Efficacy: Percent of subjects that show an increase in N-reactive T cells\|Phase 1 Humoral Immunogenicity: GMT of S-specific and N-specific antibodies\|Phase 1 Humoral Immunogenicity: GMT of neutralizing antibody\|Phase 1 Mucosal Immunogenicity: GMT of IgA antibody levels\|Phase 1 Cellular Immunogenicity: T cell activity\|Phase 2 Efficacy: Incidence and severity of COVID-19 ≥14 days after vaccination\|Phase 2 Efficacy: Mean SARS-CoV-2 viral load\|Phase 2 Efficacy: Humoral Immunogenicity - GMT of S-specific and N-specific antibodies\|Phase 2 Efficacy: Humoral Immunogenicity - GMT of neutralizing antibody\|Phase 2 Efficacy: Mucosal Immunogenicity - GMT of IgA antibody levels\|Phase 2 Efficacy: Cellular Immunogenicity - T cell activity\|Phase 2 Safety: Incidence of MAAEs and SAEs\|Phase 2 Safety: Incidence and severity of solicited local reactogenicity AEs\|Phase 2 Safety: Incidence and severity of solicited systemic reactogenicity AEs\|Phase 2 Safety: Incidence and severity of unsolicited AEs\|Phase 2 Safety: Incidence of changes of laboratory safety examinations\|Phase 2 Safety: Vital Sign - Temperature\|Phase 2 Safety: Vital Sign - Heart rate\|Phase 2 Safety: Vital Sign - Blood Pressure\|Phase 2 Safety: Vital Sign - Respiratory rate
NCT04324606	A Study of a Candidate COVID-19 Vaccine (COV001)	Active, not recruiting	Phase 1\|Phase 2	Apr/23/2020	Mar/31/2023
Alternative id - COV001 Interventions - Biological: ChAdOx1 nCoV-19\|Biological: MenACWY\|Biological: ChAdOx1 nCoV-19 full boost\|Biological: ChAdOx1 nCoV-19 half boost\|Biological: MenACWY boost\|Drug: Paracetamol\|Biological: ChAdOx1 nCoV-19 0.5mL boost\|Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)\|Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT) Study type - Interventional Study results - No Results Available Locations - University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom\|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom\|St Georges University Hospital NHS Foundation Trust, London, United Kingdom\|Imperial College Healthcare NHS Trust, London, United Kingdom\|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom\|John Radcliffe Hospital, Oxford, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 1090 Age - 18 Years to 55 Years (Adult) Outcome measures - Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases\|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)\|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms\|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms\|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)\|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests\|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes\|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by hospital admissions\|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by ICU admissions\|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by COVID-19 related deaths\|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19\|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates\|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays\|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19
NCT04957017	Effect of Hand-Washing Training in Covid-19	Completed	Not Applicable	Aug/15/2020	Jun/10/2021
Alternative id - GO 2020/192 Interventions - Behavioral: Training Study type - Interventional Study results - No Results Available Locations - Burdur Mehmet Akif Ersoy university, Burdur, Turkey Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Supportive Care Enrollment - 90 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - The Nutritional Knowledge Level Scale for Adults (NKLSA)\|Social Hand-Washing Knowledge Form
NCT04511949	COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease	Completed	Not Applicable	Jul/12/2020	Nov/30/2020
Alternative id - CREPATS 012 Interventions - Diagnostic Test: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma) Study type - Interventional Study results - No Results Available Locations - Christine KATLAMA, Paris, Ile De France, France Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 500 Age - 3 Years and older (Child, Adult, Older Adult) Outcome measures - Measure of the proportion of contact persons who have developed anti-SARS-CoV-2 antibodies (secondary transmission rate) within the same household of a subject who had a COVID-19 disease assessed by a rapid diagnostic-oriented test
NCT05249777	A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule as a Combination Regimen With Standard Treatment for Patients With Mild to Moderate COVID-19	Recruiting	Phase 3	Jan/06/2022	Nov/30/2022
Alternative id - TD0069-COVID19-III Interventions - Drug: TD0069 hard capsule\|Drug: TD0069 Placebo Study type - Interventional Study results - No Results Available Locations - Traditional Medicine Institute in Ho Chi Minh City, Ho Chi Minh City, Ho Chi Minh, Vietnam Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 570 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - The rate of patients with serious diseases/conditions related to Covid-19\|Daily symptoms improvement\|The rate and severity grade of adverse events related to the investigational product\|Time to clinical symptom resolution\|The rate of Covid-19 diseases according to traditional medicine\|Time to symptom resolution of Covid-19 diseases according to traditional medicine\|The length of hospital stay\|The rate of Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs\|The quality of life at day 0, day 7, day 14, and day 28
NCT05076266	COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation	Recruiting		Dec/02/2021	Jul/01/2022
Alternative id - EAQ201\|NCI-2021-05681 Interventions - Other: Questionnaire Study type - Observational Study results - No Results Available Locations - University of Michigan, Ann Arbor, Michigan, United States Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 1000 Age - 45 Years to 75 Years (Adult, Older Adult) Outcome measures - Compare the proportion of WOC EAQ201 participants who experience COVID-related financial hardship vs non-WOC EAQ201 participants\|Compare the proportions of WOC vs non-WOC EAQ201 participants with COVID-related change in their material condition, a composite measure\|Compare the proportions of WOC vs non-WOC EAQ201 participants with COVID-specific perceived financial distress\|Compare the proportion of WOC in TMIST participants vs EAQ201 participants
NCT04747405	Evaluation of Psychological Impact of Group Therapy for Patients Who Have Been Hospitalized in Intensive Care During COVID-19 Pandemic: Exploratory Study	Not yet recruiting	Not Applicable	Feb/22/2021	Aug/22/2022
Alternative id - CHMS20009 Interventions - Other: therapy group Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - prevalence of post traumatic stress syndrome
NCT04334434	Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)	Completed	Not Applicable	Jul/30/2020	Dec/15/2020
Alternative id - 002 Interventions - Other: Telerehabilitation Study type - Interventional Study results - No Results Available Locations - Istanbul university Cerrahpasa, Istanbul, Turkey Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Prevention Enrollment - 30 Age - 65 Years and older (Older Adult) Outcome measures - Physical Activity Scale for the Elderly\|Nottingham Health Profile\|Loneliness Scale for the Elderly
NCT05265390	The Effect of Video Information on Anxiety in Adolescents Having rRT-PCR Test During Corona Virus Pandemic	Not yet recruiting	Not Applicable	Mar/01/2022	Feb/28/2023
Alternative id - Interventions - Other: Adolescents watching an informational video Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Health Services Research Enrollment - 270 Age - 12 Years to 18 Years (Child, Adult) Outcome measures - State Anxiety Inventory Score Form - 1 (STAI FORM -1)\|Trait Anxiety Score Form - 2 (STAI FORM -2)\|Coronavirus Anxiety Scale (CAS)
NCT05059106	EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19	Recruiting	Phase 2\|Phase 3	Jun/01/2021	Oct/30/2022
Alternative id - FUES02 Interventions - Biological: Half dose of ChAdOx1 nCoV-19 (AZD1222)\|Biological: Standard dose of ChAdOx1 nCoV-19 (AZD1222) Study type - Interventional Study results - No Results Available Locations - Federal University of Espirito Santo, Vitória, Espirito Santo, Brazil Study designs - Allocation: Non-Randomized\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 29637 Age - 18 Years to 49 Years (Adult) Outcome measures - Incidence of new cases\|Number of deaths\|number of hospital admissions\|number of intensive care unit (ICU) admissions\|number of tests (RT-PCR)\|Viral Neutralization Assay\|serological assay\|IgM\|IgG\|systemic soluble factors\|Antigen-specific stimulation of peripheral blood mononuclear cells\|Lymphocyte investigation\|Cytokine investigation
NCT05067946	Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines	Not yet recruiting	Phase 2\|Phase 3	Oct/01/2021	Oct/01/2023
Alternative id - GX-19N-HV-004 Interventions - Biological: GX-19N\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Prevention Enrollment - 14000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - First occurrence of COVID-19 at least 14 days after the second vaccination\|Incidence of severe solicited adverse events (AEs)\|Incidence of AEs and Serious AEs (SAEs) after each vaccination\|Incidence of SAE, and Adverse events of special interest (AESIs), which relevant to COVID-19 including possible vaccine-enhanced disease\|First occurrence of severe COVID-19 at least 14 days after the second vaccination\|Cell-mediated immune responses after vaccination\|Antibody responses after vaccination
NCT04416308	COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)	Completed	Not Applicable	May/29/2020	Oct/12/2020
Alternative id - 35RC20_9716 Interventions - Diagnostic Test: NG test\|Diagnostic Test: Blood test\|Behavioral: Self-questionnary Study type - Interventional Study results - No Results Available Locations - CENTRE HOSPITALIER de VITRE_ Saint Jean (La Guerche), La Guerche de Bretagne, La Guerche-de-Bretagne, France\|Centre Hospitalier de Fougeres, Fougères, France\|Centre Hospitalier Grand Fougeray, Grand-Fougeray, France\|Centre Hospitalier de La Roche Aux Fees, Janzé, France\|Centre Hospitalier Montfort-Sur-Meu, Montfort sur Meu, France\|Centre Hospitalier de Redon Carentoir, Redon, France\|Chu Rennes, Rennes, France\|Centre Hospitalier St Meen Le Grand, Saint-Méen-le-Grand, France\|CENTRE HOSPITALIER VITRE_Simone Veil, Vitré, France Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Diagnostic Enrollment - 9453 Age - 18 Years and older (Adult, Older Adult) Outcome measures - rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.\|a) Validation of the Biotech NG test:\|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG\|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM.\|b) Risk of presence of anti SARS-CoV-2 antibodies in function:\|c) Risk of presence of anti SARS-CoV-2 antibodies in function:\|d) Description of the experience and behavioral changes related to the epidemic,\|e) Evolution of seroprevalence over time:
NCT05087225	Suspicion of Hypoglycemic Effect of mRNA Based Covid-19 Vaccines (Polyethylene Glycol) Will Happen , Observational Study on Diabetic Patients at Saudia Arabia	Enrolling by invitation		Nov/11/2021	Apr/01/2022
Alternative id - ministry of health saudia Interventions - Biological: polyethelyene glycol Study type - Observational Study results - No Results Available Locations - ministry of health , First health cluster , Riaydh, Riyadh, N/A (Non-US), Saudi Arabia Study designs - Observational Model: Case-Only\|Time Perspective: Retrospective Enrollment - 50 Age - 12 Years to 80 Years (Child, Adult, Older Adult) Outcome measures - hypoglycemic effects of polyethylene glycol as excipients covid-19 vaccines at diabetic patients\|measurement of blood glucose one month after first or second shot of mRNA based covid-19 vaccines\|enhancements of hypoglycemic effects of metformin and insulin by PEG
NCT04830761	Behavior Change in Context to Contain the Spread of COVID-19	Recruiting	Not Applicable	Mar/26/2021	Apr/01/2022
Alternative id - 2021-00164 Interventions - Behavioral: Motivation\|Behavioral: Habit\|Behavioral: Social Study type - Interventional Study results - No Results Available Locations - University of Bern, Bern, Switzerland Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Prevention Enrollment - 710 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Average frequency of correct hand hygiene behaviour at key times\|Frequency of hand hygiene behaviour at key times, but not correctly\|Self-reported behavioural intention\|Mean score of self-reported fife risk perception items\|Mean score of eight self-reported outcome-expectancies items\|Mean score of four self-reported coping planning items\|Mean score of three self-reported action planning items\|Habit strength assessed with the self-report habit index (SRHI)\|Mean score of three self-reported injunctive norm items\|Mean score of two self-reported descriptive norm items\|Mean score of six self-reported attitude items\|Mean score of three self-reported action control items\|User engagement assessed with the DBCI Engagement Scale\|Intervention usability using the System Usability Scale (SUS)\|Satisfaction using the ZUF-8 (Original Englische Version CSQ-8)\|Mean score of intervention fidelity items\|Self-reported flu-like infection symptoms\|Self-reported statement of the occurrences of Covid-19.\|Mean score of eight self-reported self-efficacy items
NCT04559542	Body Weight Regulation, Disordered Eating Behaviour, and Experiences of Sexual Harassment in Female Martial Art Athletes	Completed		Sep/10/2020	May/30/2021
Alternative id - 20/00378 Interventions - Study type - Observational Study results - No Results Available Locations - Norwegian school of sport sciences, Oslo, Norway Study designs - Observational Model: Cohort\|Time Perspective: Cross-Sectional Enrollment - 33 Age - 16 Years to 40 Years (Child, Adult) Outcome measures - Low energy availability for females questionnaire (LEAF-Q)\|Eating disorder examination questionnaire (EDE-q)\|Body Weight regulation strategies, selfreported\|Body appreciation scale (BAS-2)\|Exercise frequency, selfreported according to a designed questionnaire\|Exercise duration, selfreported according to a designed questionnaire\|Exercise motivation, selfreported according to a designed questionnaire\|Exercise program variation, selfreported according to a designed questionnaire\|Physical activity level, objectively measured\|Four day weighed diet registration; energyintake\|Four day weighed diet registration; nutrient intake\|Experiences of sexual harassment\|Effects from Covid-19 pandemic on exercise- and eating routines, designed questionnaire
NCT04817293	Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region	Recruiting		Apr/06/2021	Dec/01/2021
Alternative id - RIPH_2021_01 Interventions - Other: Questionnaire\|Other: medical consultation Study type - Observational Study results - No Results Available Locations - CH Tourcoing, Tourcoing, France Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 1000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - To compare the reasons for consultation between patients with a history of Covid 19 and those who have not been infected with SARS-CoV-2.\|To Assess the presence of somatoform disorders between COVID-19 and non-COVID-19 patients.\|To compare the quality of life of COVID-19 patients with that of non-COVID-19 patients.
NCT04830020	Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes	Completed	Phase 2	Feb/26/2021	Sep/30/2021
Alternative id - CampusBioMedico\|1ZIDES102465 Interventions - Drug: HMW-HA Study type - Interventional Study results - No Results Available Locations - Università Campus Biomedico di Roma, Roma, Italy Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 180 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Cumulative time on oxygen\|Need for advanced airway intervention or death due to COVID19;\|Rate of change of respiratory rate;\|Change in PaO2 /FiO2 ratio during treatment\|Time to discharge from hospital
NCT04397471	A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis	Not yet recruiting		May/01/2020	Dec/01/2021
Alternative id - COMET20d Interventions - Procedure: Bone Marrow Harvest Study type - Observational Study results - No Results Available Locations - Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom Study designs - Observational Model: Case-Only\|Time Perspective: Prospective Enrollment - 10 Age - 18 Years to 40 Years (Adult) Outcome measures - Determine feasibility of recruiting healthy volunteers in a clinically useful timeframe.\|Manufacture a cell-based product suitable for clinical use\|Establishment of a robust process of production\|Production of stability data to be used in the MHRA dossier for the COMET clinical trial.\|Production of cell-based products to be administered to COVID-19 patients with severe pneumonitis.\|Analysis of cells for understanding production, manufacture and related research.
NCT04958902	RESTORE in Patients Who Had COVID-19 and Close Others	Recruiting	Not Applicable	Oct/22/2021	Nov/01/2021
Alternative id - REB# 21-5394-0 Interventions - Behavioral: RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health Study type - Interventional Study results - No Results Available Locations - University Health Network, Toronto, Ontario, Canada Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 20 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in self-reported Post Traumatic Stress Disorder (PTSD) symptoms\|Change in Generalized Anxiety Disorder-7 (GAD-7)\|Change in Patient Health Questionnaire-9 (PHQ-9)\|Change in Perceived Health, Functioning, and Quality of Life (QOL)\|Change in Trauma-Related Guilt Inventory (TRGI)\|Change in Adapted Brief Grief Questionnaire\|Change in Perceived emotional social support\|Change in Mental Health Seeking Attitudes/Intention Scale
NCT04930965	Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate	Recruiting	Not Applicable	Oct/05/2021	Mar/31/2022
Alternative id - 2020-1600\|OT2 HL158260 Interventions - Behavioral: Community health worker engagement Study type - Interventional Study results - No Results Available Locations - Tulane University Medical Center, New Orleans, Louisiana, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Difference in proportion of participants "likely to vaccinate" between study arms at Month 1\|Difference in proportion of participants "likely to vaccinate" between study arms at Month 2\|Difference in proportion of participants who have received >=1 dose of vaccine between study arms at Month 1\|Difference in proportion of participants who have received >=1 dose of vaccine between study arms at Month 2
NCT05240742	CORona (COVID-19) Follow Up Study: Epidemiology, Pathophysiology, Prediction, and Communication	Enrolling by invitation		Oct/01/2021	Dec/31/2022
Alternative id - METC2021-2990 Interventions - Other: no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts Study type - Observational Study results - No Results Available Locations - Maastricht University Medical Center+, Maastricht, Netherlands Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 5000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Prevalence of long COVID complaints (based on data from all 7 cohorts)\|(Health-related) Quality of life (measured in all 7 cohorts)\|Anxiety and depression (measured in all 7 cohorts)\|Prevalence of thrombo-embolic complications (not measured in all 7 cohorts)\|Physical functioning (not measured in all 7 cohorts)\|Prevalence of cardiovascular diseases (not measured in all 7 cohorts)\|Prevalence of endothelium dysfunction (not measured in all 7 cohorts)\|Disease severity during intensive care unit stay (not measured in all 7 cohorts)
NCT04591717	COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers	Active, not recruiting	Phase 1	Oct/19/2020	Nov/19/2021
Alternative id - QUILT-COVID-19-hAd5-Vaccine Interventions - Biological: hAd5-S-Fusion+N-ETSD vaccine Study type - Interventional Study results - No Results Available Locations - Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States\|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 34 Age - 18 Years to 55 Years (Adult) Outcome measures - Incidence of MAAEs and SAEs\|Incidence and severity of solicited local reactogenicity AEs\|Incidence and severity of solicited systemic reactogenicity AEs\|Incidence and severity of unsolicited AEs\|Incidence of abnormal changes of laboratory safety examinations\|Vital Signs - Fever\|Vital Signs - Tachycardia\|Vital Signs - Bradycardia\|Vital Signs - Hypertension\|Vital Signs - Hypotension\|Vital Signs - Respiratory Rate\|GMFR in IgG titer\|GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus\|Percentage of subjects who seroconverted\|GMFR in neutralizing antibody\|GMT\|Seroconversion rate of neutralizing antibody\|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein\|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein
NCT05109559	Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine	Recruiting	Phase 1\|Phase 2	Dec/20/2021	May/01/2023
Alternative id - VAC31518COV2012 Interventions - Biological: Full dose of Ad26.COV2. 5x10^10vp\|Biological: Half dose of Ad26.COV2. 2.5x10^10vp Study type - Interventional Study results - No Results Available Locations - Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi,, Bangkok, Thailand Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 690 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Frequency of solicited reportable local adverse event after vaccination\|Frequency of solicited reportable systemic adverse event after vaccination\|Frequency of all unsolicited AEs\|GMT Anti-S IgG at baseline\|GMT Anti-S IgG at 7 days after vaccination in subset subjects\|GMT Anti-S IgG at 14 days after vaccination in subject subjects\|GMT Anti-S IgG at 28 days after vaccination\|GMT Anti-S IgG at 84 days after vaccination\|GMT Anti-S IgG at 168 days after vaccination\|GMT Anti-S IgG at 336 days after vaccination\|GMFR changed from baseline in anti-S IgG GMT at 28 days after vaccination\|GMFR changed from baseline in anti-S IgG GMT at 84 days after vaccination\|GMFR changed from baseline in anti-S IgG GMT at 168 days after vaccination\|GMFR changed from baseline in anti-S IgG GMT at 336 days after vaccination\|Anti-S IgG Seroresponses changed from baseline at 28 days after vaccination\|Anti-S IgG Seroresponses changed from baseline at 84 days after vaccination\|Anti-S IgG Seroresponses changed from baseline at 168 days after vaccination\|Anti-S IgG Seroresponses changed from baseline at 336 days after vaccination\|GMT measured by pseudovirus neutralization assay (pNA) and microneutralization assay (mNA) Neutralizing antibody titer 50 at baseline\|GMT measured by pseudovirus neutralization assay (pNA) and microneutralization assay (mNA) Neutralizing antibody titer 50 at 28 days after Ad26.COV2.S vaccination\|GMT measured by pseudovirus neutralization assay (pNA) and microneutralization assay (mNA) Neutralizing antibody titer 50 at 84 days after Ad26.COV2.S vaccination\|GMT measured by pseudovirus neutralization assay (pNA) and microneutralization assay (mNA) Neutralizing antibody titer 50 at 168 days after Ad26.COV2.S vaccination\|GMT measured by pseudovirus neutralization assay (pNA) and microneutralization assay (mNA) Neutralizing antibody titer 50 at 336 days after Ad26.COV2.S vaccination\|GMFR changed from baseline (pre-boost titer) in NT50 measured by pNA and mNA against SARS-CoV-2 Delta and Wildtype at 28 days after Ad26.COV2.S vaccination\|GMFR changed from baseline (pre-boost titer) in NT50 measured by pNA and mNA against SARS-CoV-2 Delta and Wildtype at 84 days after Ad26.COV2.S vaccination
NCT04872686	Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx	Completed	Phase 3	Apr/10/2021	May/30/2021
Alternative id - BRiCM LABS BANGASAFE SPRAY Interventions - Drug: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient\|Drug: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity\|Drug: 0.6% PVP-I Oral and nasal spray to healthy volunteer\|Other: Oral and nasal spray by distilled water to control group Study type - Interventional Study results - No Results Available Locations - Bangladesh Reference Institute for Chemical Measurements, Dhaka, Dhanmondi, Bangladesh\|Dhaka Medical College Hospital, Dhaka, Bangladesh\|Kurmitola General Hospital, Dhaka, Bangladesh\|Kuwait-Moitree Hospital, Dhaka, Bangladesh Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 798 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Viral concentration assessment in Naso-Oropharynx by applying 0.6% PVP-I on COVID-19 positive, moderately ill admitted patient\|Effectiveness of 0.6% PVP-I assessment through viral concentration measurement\|TSH, FT3, FT4 and Unirine iodine concentration determination for assessing side effect on thyroid function after using 0.6% PVP-I oronasal spray on healthy volunteer\|Serum creatinine concentration determination for assessing side effect on kidney function after using 0.6% PVP-I oronasal spray on healthy volunteer

Export (.csv)